#ASCO19: Amgen grows more confident in KRAS G12C drug with a positive snapshot for lung cancer — shares spike
CHICAGO — Amgen came to ASCO as the leader in the race to develop the first targeted KRAS G12C drug for cancer. And even as critics have started to take a shot at the field, they’re determined to keep the lead straight through what’s shaping up as a hectic race among a growing set of rivals.
Basic subscription required
Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.